

Benralizumab for treating severe eosinophilic asthma

Information for the public

Published: 6 March 2019

www.nice.org.uk

Benralizumab is available on the NHS. It is a possible additional treatment for severe eosinophilic asthma in adults who are taking high-dose inhaled corticosteroids plus a long-acting beta-agonist, if:

- the number of eosinophils in their blood has been 300 cells/microlitre or more, and their asthma worsened and needed systemic corticosteroids at least 4 times in the last 12 months or they have been taking oral corticosteroids for the last 6 months or
- the number of eosinophils in their blood has been 400 cells/microlitre or more, and their asthma worsened and needed systemic corticosteroids at least 3 times in the last 12 months.

Benralizumab can be continued after 12 months only if it is working well enough.

If you are not eligible for benralizumab but are already taking it, you should be able to continue until you and your doctor decide when best to stop.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. Read more about [making decisions about your care](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The [NHS website](#) may be a good place to find out more.

These organisations can give you advice and support:

- [Asthma UK](#), 0300 222 5800
- [Asthma Relief Charity](#), 01793 524004

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-3262-7